sdü tıp fak derg

Medical Journal of Süleyman Demirel University

2602-2109

Süleyman Demirel Üniversitesi

10.17343/sdutfd.403187

Clinical Sciences

Klinik Tıp Bilimleri

HUZUREVİNDE YAŞAYAN YAŞLILARDAKİ İLAÇ PROFİLİNİN DEĞERLENDİRİLMESİ: İLAÇ-İLAÇ ETKİLEŞİMİ ANALİZİ

https://orcid.org/0000-0002-7933-0453

Savran

Mehtap

Aşcı

Halil

12 01 2018

25 4 361 369 03 08 2018 04 12 2018

1994

Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi

Giriş: Günümüzde hastalıklarınönlenmesi ve/veya erken dönemde teşhis/tedavi edilmesi ile ortalama yaşamsüresi artmıştır. Artan yaşam süresi kronik hastalıklar nedeniyle polifarmasiyiberaberinde getirmekte bu nedenle yaşlı bakımında kalitenin azalmasına ve yaşlıhizmet maliyetinin artışına yol açmaktadır.Amaç: Bu çalışma Isparta Özel Huzurevive Yaşlı Bakım Merkezi’nde yaşayan yaşlılardaki polifarmasi varlığı, pDDI’larınsıklığı ve bunların tiplerinin değerlendirilmesini amaçlamaktadır.Materyal- Metod: Bu çalışma Isparta Özel Huzurevi ve Yaşlı BakımMerkezi’nde kesitsel tanımlayıcı nitelikte planlandı. Çalışma için Ağustos 2017tarihinde huzurevinde yaşayan yaşlıların hasta dosyaları tarandı. VerilerLexi-Interact programı ile değerlendirildi.Bulgular: Huzurevindeyaşayan 61 yaşlının yaş ortalaması 79,16± 7,57 (65-94) yıl iken, yaşlıların 24’ü (% 39,3) kadın, 37’si erkek (%60,7) idi. Huzurevi sakinlerinin huzurevinde kalma süresi ortalama 6,65 ± 8,53 (1- 35 yıl) yıl idi.Huzurevinde kalan yaşlılarda kronikhastalık olarak en sık hipertansiyon, gastroözefagial reflu, benign prostathipertrofisi ve diabetes mellitus saptandı.Huzurevinde yaşayan 65 yaş üzeriyaşlıların kullandıkları ilaçlar değerlendirildiğinde kişi başı ortalama ilaçsayısı 3,14 ± 2,99 (0-12 adet) olarak bulundu. Polifarmasi ve pDDI arasındaistatistiksel olarak anlamlı bir ilişki tespit edildi (p<0.05)Tartışma:Yaşla birlikte artan ko-morbid hastalıklara bağlı polifarmasi ve yaşla birlikteortaya çıkan farmakokinetik ve farmakodinamik değişiklikler, yaşlıları adversilaç reaksiyonlarına yatkın hale getirir. Bu nedenle huzurevinde kalanyaşlıların ilaç profilleri değerlendirilirken ilaçların potansiyel etkileşimleryönünden değerlendirilmesinin uygun olacağı kanaatindeyiz.‘Evaluation of Drug Profiles inElderly Living in Nursing Homes: Drug-Drug Interaction Analysis’SummaryIntroduction: Today, the average life span hasincreased with the prevention of diseases and / or early diagnosis / treatment.Increased life span brings polypharmacy due to chronic diseases, which leads todecrease of quality in elderly care and increase of elderly service cost.Objective: This study aims toevaluate the prevalence of polypharmacy, pDDIs and their types in elderlyliving in Isparta Private Nursing Home and Elderly Care Center.Materialsand methods:This study was planned as a cross-sectional descriptive feature in IspartaPrivate Nursing Home and Elderly Care Center. The patient files of the elderlyliving in the nursing home were screened on August 2017 for the study. The datawas evaluated using the Lexi-Interact program.Findings: The mean age of 61 elderlyliving in nursing homes was 79,16 ± 7,57 (65-94) years whereas 24 (39,3%) ofthe elderly were female and 37 were male (60,7%). The average length of stay innursing home residents was 6.65 ± 8.53 (1- 35 years). Hypertension,gastroesophageal reflux, benign prostatic hypertrophy and diabetes mellituswere the most common chronic diseases. The average number of medicines perperson was 3.14 ± 2.99 (0-12). A statistically significant relationship wasfound between polypharmacy and pDDI (p = 0,000)Conclusion: Pharmacokinetic andpharmacodynamic changes associated with polypharmacy and age associated withincreasing co-morbid diseases with age make the elderly susceptible to adversedrug reactions. For this reason, we think that it would be appropriate toevaluate drugs in terms of potential interactions when evaluating medication profiles of elderlypeople living in nursing homes.

Yaşlı Huzurevi Polifarmasi

1. Bahar A, Parlar S. Yaşlılık ve evde bakım. Fırat Sağlık Hizmetleri Derg, 2007; 2(4): 33–9.

2. Kirchmayer U, Mayer F, Basso M, De Cristofaro R, Mores N, Cappai G, et al. Polypharmacy in the elderly: A population based cross-sectional study in Lazio, Italy. Eur Geriatr Med, 2016; 7(5): 484–7.

3. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf, 2014;13(1): 57-65.

4. Kerry Z. Yaşlılarda doğru ilaç kullanımı Rational drug use in elderly. 2015;62–73.

5. Taşkın Şayir Ç, Aslan Karaoğlu S, Evcik Toprak D. Evaluation of polypharmacy and complementary therapy use in patients >=65 years, attending to Family Medicine Outpatient Clinic of Şişli Etfal Training and Research Hospital. Turkiye Aile Hekim Derg, 2014; 18(1): 35–41. 6. Hovstadius B, Petersson G. Factors Leading to Excessive Polypharmacy. Clin Geriatr Med, 2012; 28(2): 159–72.

7. Olumuyiwa JF, Akinwumi AA, Ademola OA, Oluwole BA, Ibiene E. Prevalence and Pattern of Potential Drug-Drug Interactions among Chronic Kidney Disease patients in South-Western Niger. Niger Postgrad Med J, 2017; 24(2): 88–92.

8. Borges TL, Vedana KGG, Castilho ECD, Miasso AI. Factors Associated with Potential Drug-Drug Interactions in Patients Attended in Primary Health Care: A Focus on Mental Health. Issues Ment Health Nurs, 2017; 0(0): 1–6.

9. Mallet L, Spinewine A, Huang A. Prescribing In Elderly People 2 The challenge of managing drug interactions in elderly people. Lancet, 2007; 370: 185–91.

10. Jazbar J, Locatelli I, Horvat N, Kos M. Clinically relevant potential drug–drug interactions among outpatients: A nationwide database study. Res Soc Adm Pharm , 2017; Available from: http://linkinghub.elsevier.com/retrieve/pii/S1551741117300414

11. van Leeuwen RWF, Brundel DHS, Neef C, van Gelder T, Mathijssen RHJ, Burger DM, et al. Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer, 2013; 108(5): 1071–8.

12. Bjerrum, L Rosholm, JU Hallas, J Kragstrup J. Methods for estimating the occurence of polypharmacy by means of prescrition database. Eur J Clin Pharmacol, 1997; 53(1): 7–11.

13. Özdemir L, Koçoğlu G, Sümer H, Nur N, Polat H, Aker A, et al. Sivas İl Merkezinde Yaşlı Nüfusta Bazı Kronik Hastalıkların Prevalansı ve Risk Faktörleri. C. Ü. Tıp Fakültesi Dergisi, 2005; 27 (3): 89 – 94,

14. Dökmeci D. Yaşlıda Polifarmasi ve Toksisite. Türkiye Klin J Surg Med Sci, 2006; 2(46): 53-8

15. Arslan Ş, Atalay A, Kutsal GY. Yaşlılarda i̇laç tüketi̇mi̇. Turkish J Geriatr, 2000; 3(2): 56–60.

16. Husson N, Watfa G, Laurain M, Perret-Guillaume C, Niemier J, Miger P, et al. Characteristics of polimedicated (>4) elderly: a survey in a community-dwellin population aged 60 years and over. J Nutr Heal Aging, 2014;18(1): 87–91.

17. Niclós G, Olivar T, Rodilla V. A cross-sectional evaluation of the prevalence and detection of predictors of polypharmacy amongst adult in Spain. Int J Pharm Pract, 2017;9–11.

18. Feng X, Tan X, Riley B, Zheng T, T B, U S. Polypharmacy and Multimorbidity Among Medicaid Enrollees: A Multistate Analysis. Popul Heal Manag, 2017; Epub ahead.

19. Goldberg RM, Mabee J, Chan L, Wong S. Drug-drug and drug-disease interactions in the ED: Analysis of a high- risk population. Am J Emerg Med, 1996; 14(5): 447–50.

20. Dookeeram D, Bidaisee S, Paul JF, Nunes P, Robertson P, Maharaj VR, et al. Polypharmacy and potential drug–drug interactions in emergency department patients in the Caribbean. Int J Clin Pharm, 2017 Aug 9. doi: 10.1007/s11096-017-0520-9.

21. Marusic S, Bacic-Vrca V, Obreli Neto PR, Franic M, Erdeljic V, Gojo-Tomic N. Actual drug-drug interactions in elderly patients discharged from internal medicine clinic: A prospective observational study. Eur J Clin Pharmacol, 2013; 69(9): 1717–24.

22. Secoli S-R, Figueras A, Lebrao ML, Dias de Lima F, Santos LF. Risk of Potential Drug-Drug Interactions among brazilian eldery. Drugs Aging, 2010; 27(9): 759–70.

23. Ascı H, Sönmez Y, Cankara Fatma N, Yeşilot Ş, Yıldırım MK. Investigation of the presence of potential drug-drug interactions in the adult intensive care unit : a retrospective study. Med J SDU, 2016; 23(3): 87–96.

24. Johnell K, Klarin I. The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600,000 elderly patients from the Swedish Prescribed Drug Register. Drug Saf, 2007; 30(10): 911–8.

25. Gülçebi İM, Küçükibrahimoğlu E, Karaalp A, Sarıkaya Ö, Demirkapu M, Onat F, et al. Potential drug-drug interactions in a medical intensive care unit of a university hospital. Turk J Med Sci, 2016; 46(3): 812–9.

26. Egger S, Drewe J, Schlienger R. Potential drug–drug interactions in the medication of medical patients at hospital dis- charge. Eur J Clin Pharmacol, 2003; 58: 773–8.

27. Luxembourg: Menarini International O.L.S.A. Keral (dexketoprofen) [summary of product characteristics]. [Internet]. 2012. Available from: https://myhealthbox.eu/en/view/1552144/c0fcf0d101a3aeb3ad4ab135c37392ce/leaflet

28. Luxembourg: Menarini International O.L.S.A. Enantyum (dexketoprofen) [summary of product characteristics] [Internet]. 2012. Available from: http://www.shijiebiaopin.net/upload/product/201462920485230.pdf

29. Luxembourg: Menarini International Operation Luxembourg S.A. Ketesse (dexketoprofen) [summary of product characteristics] [Internet]. 2013. Available from: http://www.meppo.com/pdf/drugs/966-KETESSE-1331886339.pdf